Two-year clinical outcomes of staged transcatheter mitral edge-to-edge repair after transcatheter aortic valve replacement
Preprint
Abstract
Background: Residual significant mitral regurgitation (MR) can increase the risk of adverse events following transcatheter aortic valve replacement (TAVR). The clinical benefits of staged transcatheter edge-to-edge repair (TEER) post-TAVR remain underexplored. This study aimed to investigate clinical outcomes of staged TEER for residual significant MR post-TAVR. Methods: This observational study included 314 consecutive patients with chronic residual grade 3+ or 4+ MR at 30 days follow-up post-TAVR, with 104 (33.1%) treated with staged TEER (TEER group) and 210 (66.9%) with medical therapy alone (MT group). The primary composite outcomes were all-cause mortality and heart failure (HF) hospitalization at 2 years. Additional analysis, including changes in MR grade and the New York Association (NYHA) functional classification, and subgroup outcome comparisons based on MR etiology were also conducted. Results: The rate of primary composite outcome was lower in the TEER group than that in the MT group (33.7% vs. 48.1%, p = 0.015). Significant improvement in MR grade and NYHA class was observed in the TEER group after 2 years. Subgroup analysis demonstrated that, among patients with degenerative MR, a lower incidence of composite outcome and HF hospitalization was observed in the TEER group (hazard ratio: 0.35; 95% confidence interval: 0.23?0.53, p < 0.001). Conclusions: Staged TEER post-TAVR was associated with reduced MR and improved clinical outcomes. The clinical significance of MR post-TAVR should be carefully evaluated, and TEER should be considered for patients with significant residual MR, particularly those with degenerative MR.Keywords
All Related Versions
- Published version: The American Journal of Cardiology, 224, 46.
This publication has 19 references indexed in Scilit:
- Safety and Feasibility of Staged Versus Concomitant Transcatheter Edge-to-Edge Mitral Valve Repair After Transcatheter Aortic Valve ImplantationThe American Journal of Cardiology, 2023
- Effect of Transcatheter Aortic Valve Replacement on Concomitant Mitral Regurgitation and Its Impact on MortalityJACC: Cardiovascular Interventions, 2021
- STS-ACC TVT Registry of Transcatheter Aortic Valve ReplacementJACC, 2020
- Transcatheter Edge-to-Edge Mitral Valve Repair With the MitraClip G4 SystemJACC: Cardiovascular Interventions, 2020
- Transcatheter Aortic Valve Replacement in Patients With Aortic Stenosis and Mitral RegurgitationThe Annals of Thoracic Surgery, 2017
- 5-year outcomes of transcatheter aortic valve replacement or surgical aortic valve replacement for high surgical risk patients with aortic stenosis (PARTNER 1): a randomised controlled trialThe Lancet, 2015
- Meta-Analysis of the Impact of Mitral Regurgitation on Outcomes After Transcatheter Aortic Valve ImplantationThe American Journal of Cardiology, 2015
- Hemodynamic results and changes in myocardial function after transcatheter aortic valve implantationAmerican Heart Journal, 2010
- Determinants of operative mortality in valvular heart surgeryThe Journal of Thoracic and Cardiovascular Surgery, 2006
- Valve Repair Versus Replacement For Mitral Insufficiency: When Is A Mechanical Valve Still Indicated?The Journal of Thoracic and Cardiovascular Surgery, 1998